These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 37731014)

  • 1. Extending dupilumab dosing intervals in atopic dermatitis: A prospective observational study in a South European tertiary hospital.
    Valente C; Farinha P; Duarte B
    J Eur Acad Dermatol Venereol; 2024 Feb; 38(2):e193-e194. PubMed ID: 37731014
    [No Abstract]   [Full Text] [Related]  

  • 2. Biological Tipping Point in Patients with Atopic Dermatitis Treated with Different Dosing Intervals of Dupilumab.
    Dekkers C; der Wal MMV; El Amrani M; Luin MV; Bakker DS; Bruin-Weller M; van Wijk F
    J Invest Dermatol; 2023 Sep; 143(9):1822-1825.e3. PubMed ID: 36997108
    [No Abstract]   [Full Text] [Related]  

  • 3. Evaluation of dupilumab dosing regimen in patients with persistently controlled atopic dermatitis.
    Sánchez-García V; Navarro-Triviño FJ; Silvestre JF
    J Eur Acad Dermatol Venereol; 2023 Dec; 37(12):e1426-e1429. PubMed ID: 37458506
    [No Abstract]   [Full Text] [Related]  

  • 4. Long-term drug survival of dupilumab and associated predictors in moderate-to-severe atopic dermatitis: A real-world prospective cohort study.
    Pezzolo E; Rossi M; Caroppo F; Bianchelli T; Belloni Fortina A; Giacchetti A; Calzavara Pinton P; Naldi L
    J Eur Acad Dermatol Venereol; 2023 Jun; 37(6):e757-e759. PubMed ID: 36662631
    [No Abstract]   [Full Text] [Related]  

  • 5. EASI p-EASI: Predicting disease severity in atopic dermatitis patients treated with dupilumab using a combination of serum biomarkers.
    Bakker DS; Ariens LFM; Giovannone B; Hijnen D; Delemarre EM; Knol E; Nierkens S; de Bruin-Weller MS; Thijs JL; Drylewicz J
    Allergy; 2020 Dec; 75(12):3287-3289. PubMed ID: 33305359
    [No Abstract]   [Full Text] [Related]  

  • 6. Real-life long-term efficacy of dupilumab in adults with moderate to severe atopic dermatitis: Results of a cohort study.
    Guédon C; Tauber M; Linder C; Paul C; Shourick J
    Ann Dermatol Venereol; 2023 Sep; 150(3):215-216. PubMed ID: 37598014
    [No Abstract]   [Full Text] [Related]  

  • 7. Reported Pregnancy Outcomes in Women With Severe Atopic Dermatitis Treated With Dupilumab: A Systematic Review.
    Akuffo-Addo E; Nicholas MN; Lansang P
    J Cutan Med Surg; 2023; 27(2):177-178. PubMed ID: 36721993
    [No Abstract]   [Full Text] [Related]  

  • 8. Emerging Role of Atopic Dermatitis Control Tool in Long-Term Monitoring of Patients With Moderate-to-Severe Atopic Dermatitis Treated With Dupilumab.
    Cioppa V; Lazzeri L; Carraro A; De Piano E; Falcinelli F; Galluzzo M; Pallotta S; De Pità O; Russo F
    Dermatitis; 2024; 35(S1):S107-S108. PubMed ID: 37594754
    [No Abstract]   [Full Text] [Related]  

  • 9. Successful dose reduction of dupilumab in atopic dermatitis.
    Ardern-Jones MR; Buchanan EE; Njungu S; O'Driscoll D
    Br J Dermatol; 2023 Apr; 188(5):678-679. PubMed ID: 36662536
    [No Abstract]   [Full Text] [Related]  

  • 10. Dose reduction of dupilumab in atopic patients with controlled atopic dermatitis: A safe and effective practice?
    Mastorino L; Gelato F; Richiardi I; Cavaliere G; Quaglino P; Ortoncelli M; Ribero S
    J Eur Acad Dermatol Venereol; 2023 May; 37(5):e691-e692. PubMed ID: 36688263
    [No Abstract]   [Full Text] [Related]  

  • 11. Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: Results of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry.
    Bosma AL; de Wijs LEM; Hof MH; van Nieuwenhuizen BR; Gerbens LAA; Middelkamp-Hup MA; Hijnen D; Spuls PI
    J Am Acad Dermatol; 2020 Nov; 83(5):1375-1384. PubMed ID: 32485210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. No association between dupilumab use and short-term cancer development in atopic dermatitis patients.
    Owji S; Ungar B; Dubin DP; Poplausky D; Young JN; Ghalili S; Han J; Srinivasan D; Packer S; Pavel AB; Correa da Rosa J; Guttman-Yassky E; Gulati N
    J Allergy Clin Immunol Pract; 2023 May; 11(5):1548-1551. PubMed ID: 36581076
    [No Abstract]   [Full Text] [Related]  

  • 13. Benefits of treatment with dupilumab for children aged 6-11 years with severe atopic dermatitis.
    Br J Dermatol; 2023 Jul; 189(2):e39. PubMed ID: 37459131
    [No Abstract]   [Full Text] [Related]  

  • 14. Dupilumab for atopic dermatitis during pregnancy and breastfeeding: Clinical experience in 13 patients.
    Escolà H; Figueras-Nart I; Bonfill-Orti M; Coll Puigserver N; Martin-Santiago A; Rodríguez Serna M; Sánchez Hernández MC; Sanz-Cabanillas JL; Taberner R; Zaragoza-Ninet V; Pujol RM; Curto-Barredo L
    J Eur Acad Dermatol Venereol; 2023 Sep; 37(9):e1156-e1160. PubMed ID: 37143399
    [No Abstract]   [Full Text] [Related]  

  • 15. Dupilumab drug survival, treatment failures, and insurance approval at a tertiary care center in the United States.
    Khosravi H; Zhang S; Anderson AM; Ferris LK; Choudhary S; Patton T
    J Am Acad Dermatol; 2020 Apr; 82(4):1023-1024. PubMed ID: 31866263
    [No Abstract]   [Full Text] [Related]  

  • 16. Successful response to upadacitinib in the treatment of atopic dermatitis lesions involving sensitive and visible areas resistant to dupilumab treatment.
    Gori N; Ippoliti E; Antonelli F; Peris K; Chiricozzi A
    Clin Exp Dermatol; 2023 Apr; 48(5):558-559. PubMed ID: 36724039
    [No Abstract]   [Full Text] [Related]  

  • 17. Dupilumab provides rapid improvement for morphologic variants of paediatric atopic dermatitis: A case series.
    Kim JW; Kim M; Ahn GS; Na JI
    Indian J Dermatol Venereol Leprol; 2022; 88(6):834-839. PubMed ID: 36331828
    [No Abstract]   [Full Text] [Related]  

  • 18. Dupilumab for moderate-severe atopic dermatitis: a real-world, single-center retrospective study of 122 patients in the United States.
    Emmerich VK; Williams JA; Hrin ML; Feldman SR; Strowd LC
    Int J Dermatol; 2024 Apr; 63(4):524-525. PubMed ID: 38093434
    [No Abstract]   [Full Text] [Related]  

  • 19. Long-term real-world experience of the side effects of dupilumab in 128 patients with atopic dermatitis and related conditions aged 6 years and above: Retrospective chart analysis from a single tertiary care center.
    Parmar NV; Abdula MA; Al Falasi A; Krishna CV
    Dermatol Ther; 2022 May; 35(5):e15415. PubMed ID: 35238115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dupilumab therapy in children aged 2-12 years with uncontrolled moderate-to-severe atopic dermatitis: A Chinese real-world study.
    Zhou B; Peng C; Cao Q; Wang J; Chen X; Li J
    J Eur Acad Dermatol Venereol; 2024 Jan; 38(1):e35-e38. PubMed ID: 37565387
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.